Deka Bank Deutsche Girozentrale Revance Therapeutics, Inc. Transaction History

Deka Bank Deutsche Girozentrale

$54.1 Billion
Q4 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 86,100 shares of RVNC stock, worth $221,277. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,100

Previous 86,100 -0.0%

Holding current value

$221,277

Previous $455,000 43.08%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	BUY	$11.52 - $20.4 $691,200 - $1.22 Million	60,000 Added 229.89%	86,100 $1.22 Million
Q1 2022 Apr 28, 2022	SELL	$12.36 - $20.31 $25,956 - $42,651	-2,100 Reduced 7.45%	26,100 $507,000
Q4 2021 Feb 02, 2022	SELL	$12.46 - $27.87 $490,924 - $1.1 Million	-39,400 Reduced 58.28%	28,200 $468,000
Q1 2021 Apr 28, 2021	BUY	$24.03 - $29.97 $108,135 - $134,865	4,500 Added 7.13%	67,600 $1.86 Million
Q4 2020 Mar 12, 2021	BUY	$23.41 - $28.34 $393,288 - $476,112	16,800 Added 36.29%	63,100 $1.71 Million
Q3 2020 Oct 29, 2020	BUY	$23.23 - $34.3 $1.08 Million - $1.59 Million	46,300 New	46,300 $1.16 Million
Q4 2019 Feb 04, 2020	SELL	$11.66 - $20.15 $466,400 - $806,000	-40,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $408,800 - $580,000	-40,000 Reduced 50.0%	40,000 $550,000
Q2 2019 Aug 01, 2019	BUY	$10.67 - $15.49 $853,600 - $1.24 Million	80,000 New	80,000 $1.01 Million
Q2 2018 Aug 14, 2018	SELL	$27.45 - $33.35 $774,090 - $940,470	-28,200 Closed	0 $0
Q1 2018 May 03, 2018	BUY	$29.15 - $37.4 $822,030 - $1.05 Million	28,200 New	28,200 $847,000

Others Institutions Holding RVNC

# of Institutions

226

Shares Held

82.9M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Revance Therapeutics, Inc. Transaction History